Search Results - Nigel McCracken

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

    Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer by Sheena Bhalla, Farjana Fattah, Chul Ahn, Jessica N. Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel McCracken, David Micklem, Rolf A. Brekken, David E. Gerber

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

    Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial by Sonja Loges, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp‐Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Mattei, Walter Fiedler, Yesid Alvarado‐Valero, Isabel Ben‐Batalla, Jonas Waizenegger, Lisa-Marie Rieckmann, Melanie Janning, Maike Collienne, Charles D. Imbusch, Niklas Beumer, David Micklem, Linn Nilsson, Noëlly Madeleine, Nigel McCracken, Cristina Oliva, Claudia Gorcea-Carson, Bjørn Tore Gjertsen

    Published 2025
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: